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Abstract
Background
Structured secondary cardiovascular prevention programs (SSCP) following acute coronary
syndromes (ACS) may reduce major adverse cardiovascular events (MACE) through better
adherence to post-ACS recommendations.
Methods
Through a prospective multicenter cohort study, we compared the outcomes of two sequen-
tial post-ACS patient cohorts, the initial one receiving standard care (SC) followed by one
receiving additional interventions (SSCP) aimed at improving patient education as well as
healthcare provider and hospital systems. The primary endpoint was MACE at one year.
Secondary endpoints included adherence to recommended therapies, attendance to car-
diac rehabilitation (CR) and successful achievement of cardiovascular risk factor (CVRF)
targets.
Results
In total, 2498 post-ACS patients from 4 Swiss university hospitals were included: 1210 vs
1288 in the SC and SSCP groups, respectively. The SSCP group demonstrated a significant
increase in attendance to CR programs (RR 1.08, 95%CI 1.02–1.14, P = 0.006), despite not
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achieving the primary MACE endpoint (HR 0.97, 95%CI 0.77–1.22, P = 0.79). After age-
stratification, significant reductions in cardiac death, MI and stroke events (HR 0.53, 95%CI
0.30–0.93, P for interaction = 0.016) were observed for SSCP patients� 65 years old.
The SSCP group also scored significantly better for the LDL cholesterol target (RR 1.07,
95%CI 1.02–1.13, P = 0.012), systolic blood pressure target (RR 1.06, 95%CI 1.01–1.13,
P = 0.029) and physical activity (RR 1.10, 95%CI 1.01–1.20, P = 0.021).
Conclusions
The implementation of an SSCP post ACS was associated with an improvement in the con-
trol of CVRF and attendance to CR programs, and was also associated with significant
reductions in cardiac death, MI and stroke at one year for patients�65years old.
Introduction
The prognosis of acute coronary syndromes (ACS) has considerably improved in recent years
with the implementation of recommended post-ACS therapies.[1] In this regard, a better
understanding of therapeutic strategies resulting from evidence-based clinical research has led
to improvements in patient long-term medication compliance and clinical outcomes.[2] In
2012, the European Society of Cardiology (ESC) issued guidelines recommending the imple-
mentation of national programs at the hospital level to monitor the quality of care of ACS
patients, as well as the development of multidimensional programs based on motivational
interviewing.[3] In addition, participation in cardiac rehabilitation (CR) programs following
hospital discharge is strongly recommended to improve patient lifestyle and long-term prog-
nosis post-ACS.[4, 5] Despite all these measures, recent European observational data for ACS
patients still point to poorly controlled targets, resulting in suboptimal reductions in the inci-
dence of major adverse cardiovascular events (MACE) and participation in CR programs.
[6, 7]
In Europe, few studies have tested secondary prevention intervention programs aimed at
improving post-ACS cardiovascular outcomes. The EUROACTION study group ran a nurse-
coordinated, multidisciplinary, family-based, ambulatory prevention program for patients
with coronary heart disease (CHD). The program highlighted both the beneficial effects of a
healthier lifestyle, and demonstrable improvements in cardiovascular risk factor control.[6]
Improving quality of care is especially important towards reducing the burden of healthcare
costs associated with ACS patients, and also enables hospitals to meet benchmark criteria.[8,
9] Switzerland recently implemented a hospital payment system based on diagnostic-related
groups (DRGs), aiming among other things at being able to objectively compare healthcare
provision across hospitals.[10]
A meta-analysis previously conducted by our group showed that in-hospital, in-patient
interventions in secondary prevention could lead to a reduction in mortality, although the evi-
dence was not definitive.[11] Based on these findings, we designed a structured secondary car-
diovascular prevention program (SSCP), named ELIPS, a multi-dimEnsionaL preventIon
Program after Acute coronary Syndromes, aiming at improving the quality of care of patients
post-ACS and thereby reducing related mortality and morbidity.
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Methods
Study population
ELIPS (NCT01075867) (Protocole 07–131) is part of a collaborative research project (Inflam-
mation and acute coronary syndromes (ACS)–Novel strategies for prevention and clinical
management) supported by the Swiss National Science Foundation in 4 Swiss university hospi-
tals (Bern, Geneva, Lausanne and Zurich). Subjects� 18 years old hospitalized with a main
diagnosis of ACS were recruited from January 2009 to December 2012. ACS were defined as
symptoms compatible with angina pectoris (chest pain, breathlessness) and at least one of the
following criteria: (a) ECG ischemic changes, such as persistent or dynamic ST-segment devia-
tion, T-waves inversion, new left bundle branch block; (b) evidence of positive conventional or
high-sensitive troponin by local laboratory reference values; (c) known coronary heart disease
(CHD) defined by pre-existing myocardial infarction (MI), coronary artery bypass graft
(CABG), percutaneous coronary intervention (PCI), or�50% documented stenosis of an
epicardial coronary artery in a previous angiography.[12] Exclusion criteria comprised index
revascularization with CABG, severe physical disability, inability to give consent (dementia)
and less than 1 year of life expectancy for non-cardiac reasons. To evaluate the effectiveness of
the ELIPS intervention, we chose a prospective sequential before-after intervention design, as
is usual for complex interventions.[11] The standard care (SC) group (observation phase)
comprised patients enrolled from January 2009 to December 2010, while the ELIPS add-on
group (intervention phase) comprised patients enrolled from January 2011 to December 2012.
The centralized institutional review board (Comite´ De´partemental d’Ethique de Me´decine
Interne et Me´decine Communautaire, Hoˆpitaux Universitaires de Genève) approved the pro-
tocol (Protocole 07–131) on August 27th, 2007, and all participants gave written informed
consent.
Description of the ELIPS intervention
The ELIPS intervention includes actions at the patient, healthcare provider and healthcare sys-
tem levels aimed at improving patient outcomes through better adherence to post-ACS CR
programs.[13, 14]
ELIPS at the patient level. At the patient level, ELIPS consisted of a CR educational pro-
gram delivered to the patient at appropriate timelines and intervals, based on individually
defined needs during the post-ACS hospitalization period. Patients were encouraged to
achieve a healthy lifestyle with the support of health professionals trained in motivational
interviewing.[15] Motivational interviewing is a non-judgmental, patient-centered counselling
approach aimed at eliciting and strengthening the motivation to change.[16] Patients were
asked to self-evaluate their cardiovascular risk factors with the aid of an interactive wall chart
and invited to watch a 27-minute film (provided in the form of a DVD) portraying the real life
trajectory of a patient suffering from ACS. Patients also received personalized educational life-
style brochures and were discharged with a standardized treatment discharge card detailing
the reasons for their prescriptions, as well as a summary of their targets in secondary preven-
tion. Patient’s comprehension of point-by-point educational content was not formally evalu-
ated. A dedicated website (https://www.hug-ge.ch/elips) enabled both patients and healthcare
providers to remain up to date with the therapeutic education process and training program.
Phase 2 cardiac rehabilitation and exercise prescription was carried out in nationally registered
cardiac rehabilitation centers following hospitalization discharge.
ELIPS at the healthcare provider level. At the healthcare provider level, dedicated nurses
at each of the 4 hospitals were trained in motivational interviewing and cardiovascular health
Clinical impact of a structured secondary cardiovascular prevention program following acute coronary syndromes
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education by certified nurse specialists (Motivational Interviewing Network of Trainers).
Interviews were centred around the patient in order to resolve any ambivalent motivation
while at the same time reinforcing intrinsic motivation for change.[15]
ELIPS at the system level. At the system level, project leaders at each participating hospi-
tal were responsible for organizing a series of educational sessions to support the implementa-
tion of the ELIPS intervention. The aforementioned standardized treatment discharge cards
were aimed at relaying follow-up information to family physicians or designated cardiologists.
As is described, the ELIPS multifaceted intervention was a program with incentives for
therapeutic adherence and lifestyle modification without pharmacologic or invasive interven-
tions. As such, it may not qualify as a clinical trial. In order to ensure, however, a public record
of the study, reduce publication bias and complete fulfilment of ethical obligations towards the
participants, the study was registered with the National Institutes of Health U.S. National
Library of Medicine ClinicalTrials.gov registry. This registration process was initiated during
the first months of the SPUM-ACS (Special Program University Medicine—Acute Coronary
Syndrome, NCT01075867), after initial participant enrollment, which began in January 2009;
the registration was first posted on February 25th, 2010. The authors confirm that all ongoing
and related trials for this intervention are registered.
Study outcomes
The primary endpoint of MACE at one-year was a composite of death from any cause, recur-
rence of MI, unplanned coronary revascularization, hospitalization for unstable angina, lower
limb ischemia and stroke events. All clinical endpoints were adjudicated by a panel of indepen-
dent experts (three certified cardiologists) blinded to the allocation groups. Secondary end-
points included the documentation of recommended therapies (such as aspirin, statins, beta-
blockers or angiotensin converting enzyme (ACE) inhibitors/angiotensin receptor blockers
(ARB)) at discharge and at one-year follow-up.[17] Given the controversies over what the opti-
mal treatment duration of P2Y12 inhibitors should be, we discarded this point from endpoint
analyses. The level of attendance to CR programs was assessed based on data collected at dis-
charge (direct transfer) and at one-year follow-up, where patients were asked if they attended a
CR program (in-patient or out-patient). Recommended secondary preventive targets at one
year were defined as low-density lipoprotein (LDL) cholesterol < 1.8 mmol/l (70 mg/dl), sys-
tolic blood pressure < 140 mm Hg, fasting plasma glucose < 7 mmol/l in non-diabetic
patients, glycated haemoglobin < 7% in diabetic patients, and weight reduction of� 5% in
overweight (body mass index [BMI] 25.0–29.9 kg/m2) or obese (� 30.0 kg/m2) subjects.[6] For
behavioural outcomes, targets were defined as smoking cessation in smokers (based on 7-day
point prevalence rates), high medication adherence (defined by a score of zero using the Mor-
isky Medical Adherence Scale (MAS)), health utility index (based on the Euroqol-5 dimen-
sions (EQ-5D)), and level of physical activity (defined by at least 3 days/week vigorous-
intensity activity or 5 days/week moderate-intensity activity, according to the international
physical activity questionnaire (IPAQ)).
Statistical analysis
Data were expressed as medians ± interquartile range (IQR) for continuous variables, and as
numbers and percentages for categorical variables. Time-to-first event or composite events
were analysed censoring patients at 365 days, at death or last valid contact date. The associa-
tion between the ELIPS intervention and the primary endpoint was expressed with hazard
ratios (HR) and 95% confidence intervals (CI) using Cox regression proportional hazards. In
the multivariate model, we adjusted for age and sex. The association with one-year preventive
Clinical impact of a structured secondary cardiovascular prevention program following acute coronary syndromes
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targets’ achievement was expressed with rate ratios (RR), using the method of generalized lin-
ear regression with a log link function and Poisson pseudo-maximum likelihood estimator.
For the sample size calculation, the estimated incidence of MACE at one-year was 15% for the
control group.[18] Based on our previous meta-analysis, we hypothesized an absolute risk
reduction of 4% for the ELIPS add-on intervention group.[11] Assuming a 2-sided alpha level
of 0.05 (5% level of significance) and a power of 0.80, it was estimated that a sample size of
1158 patients per group was required in order to detect the expected effect size. To account for
potential dropouts, our overall sample size was increased by 4% to 2400 ACS patients. Statisti-
cal analyses were performed using the STATA statistical software (Version 13, STATA Corp,
College Station, TX, USA).
Results
A total of 2498 patients were included, 1210 in the SC group (2009–2010) and 1288 in the
ELIPS add-on group (2011–2012) (Fig 1). Mean age was 62.3±12.3 (the age distribution is
illustrated in S1 Fig), 21.1% were women, 54.7% had STEMI, 40.2% NSTEMI and 5.0% unsta-
ble angina (Table 1). The reported use of educational ELIPS tools by healthcare providers was
as follows: 68.6% for motivational interviewing, 54.5% for the wall chart, 68.7% for the use of
educational brochures, 74.2% for the film provided on DVD, 52.7% for the website and 82.8%
for the discharge medication card.
Except for the use of beta-blockers, no significant differences were found between the SC
and ELIPS add-on groups regarding the prescription of recommended medications at dis-
charge, or reported use of the said medications at one year (Table 2). The use of beta-blockers
was higher at one year in the ELIPS add-on group (80.2% vs. 76.0%, RR 1.05 95% CI 1.01–
1.10, P = 0.019). The rate of participation in a CR program was also significantly higher in the
ELIPS add-on arm (72.9% vs. 65.6%, RR 1.08, 95% 1.02–1.14, P = 0.006).
The one-year primary endpoint of MACE occurred in 151 patients in the SC group
(12.5%) compared to 153 patients (11.9%) in the ELIPS add-on group (age and sex adjusted
HR 0.97, 95% CI 0.77–1.22, P = 0.79) (Table 3). No significant differences were found in the
incidence of individual outcomes. The cumulative hazards curve for the composite defined
by cardiac death, MI and stroke events suggests a trend towards lower events rates in the
ELIPS add-on arm vs. SC, especially after hospital discharge (Fig 2). In post-hoc subgroup
analyses, significant reductions in cardiac death, MI and stroke events were observed in the
ELIPS add-on arm compared to patients� 65 years in the SC group (HR 0.53, 95% CI 0.30–
0.93, P for interaction = 0.016, Fig 3); the same observation was made for patients� 55 years
(Table 4); there was also a non significant trend towards a higher rate of adverse events in
patients above 75 years of age (Table 5). After adjustement for length of stay, the association
in patients� 65 year olds was attenuated (HR 0.61 (95% CI 0.35–1.09, P = 0.09), while the
interaction was still significant (P = 0.023). After adjustment for cardiac rehabilitation, the
effect size of the association for the ELIPS intervention persisted in patients� 65 years, but
with a reduction of statistical significance (HR 0.55, 95% CI 0.20–1.49, P = 0.240). Likewise,
attendance to cardiac rehabilitation was also nearly associated with significant reductions in
cardiac death, MI and stroke events (HR 0.54, 95% CI 0.26–1.14, P = 0.106), but no signifi-
cant interaction of the ELIPS intervention was found according to clinical rehabilitation
attendance (P = 0.897).
At one year, we noted a significant improvement in the ELIPS group for the achievement of
recommended targets, such as LDL cholesterol (74.4% vs 69.8%, RR 1.07, 95% CI 1.02–1.15,
P = 0.012), systolic blood pressure (73.4% vs. 66.5%, RR 1.06, 95% CI 1.01–1.13, P = 0.029) and
physical activity (54.2% vs. 48.3%, RR 1.10, 95% CI 1.01–1.20, P = 0.024) (Table 6).
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Discussion
Main findings
The implementation of the multi-dimensional secondary prevention program after ACS is fea-
sible in a variety of academic centers and is associated with an optimal reported use of educa-
tional material during patients’ hospital stay. We did not, however, observe a significant
reduction in recurrent cardiovascular events at one year in the overall cohort. In a subgroup
Fig 1. Flowchart of the studied cohort.
https://doi.org/10.1371/journal.pone.0211464.g001
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analysis, ELIPS (Structured Secondary Prevention Program) patients� 65 years may appear
to have gained additional benefit from an educational program, with a reduction in cases of
cardiac death, myocardial infarction and stroke events. However, caution is needed in the
interpretation of these findings given the post-hoc nature of the analysis and the accompanying
limitations. The overall neutral result is in part explained by a trend, although not statistically
significant, towards a higher MACE rate in patients above 75 years. We also observed an
improvement in the control of cardiovascular risk factors, such as the achievement of LDL
cholesterol targets, and the level of participation in CR programs was especially high for the
ELIPS vs. SC group (72.9% vs. 65.6; p = 0.006), which may be beneficial in the longer term.
This finding is especially relevant for the process of care and specifically for the adherence to
Table 1. Baseline characteristics of 2498 participating ACS patients.
Variables Standard Care
2009–2010
N = 1210
ELIPS add-on
2011–2012
N = 1288
P value
Socio-demographic
Age (years), mean ± SD 63.6 ± 12.6 61.2 ± 11.9 < 0.001
Women, n (%) 255 (21.1) 271 (21.0) 0.98
BMI (kg/m2), mean ± SD 27.1 ± 4.2 27.1 ± 4.3 0.74
High education level, n (%) 174 (15.0) 186 (14.8) 0.87
Medical history
Diabetes, n (%) 215 (17.8) 208 (16.2) 0.28
Hypertension, n (%) 699 (57.8) 681 (52.9) 0.013
Hypercholesterolemia, n (%) 713 (59.1) 778 (60.6) 0.44
Current smoker, n (%) 462 (38.3) 551 (42.8) 0.03
Previous MI, n (%) 209 (17.3) 178 (13.8) 0.017
Previous Stroke, n (%) 33 (2.7) 27 (2.1) 0.30
CV treatment prior ACS
Aspirin, n (%) 378 (31.2) 358 (28.0) 0.074
Statins, n (%) 372 (30.7) 354 (27.7) 0.095
Beta-blockers, n (%) 267 (22.1) 272 (21.3) 0.63
ACE inhibitors/ARB, n (%) 429 (35.5) 415 (32.6) 0.12
Hospital data
ACS diagnosis
STEMI, n (%) 639 (52.9) 725 (56.4) 0.020
NSTEMI, n (%) 510 (39.7) 493 (40.1)
Unstable angina, n (%) 51 (4.0) 75 (6.2)
Killip at admission
Class I, n (%) 1040 (88.8) 1136 (88.6) 0.21
Class II-IV, n (%) 131 (11.2) 146 (11.4)
Index revascularization
PCI with stent, n (%) 1028 (84.9) 1134 (88.0) 0.009
PCI without stent, n (%) 60 (5.0) 67 (5.2)
Conservative, n (%) 123 (10.2) 87 (6.8)
Length of stay, mean (±SD) 4.9 ± 5.3 4.2 ± 3.9 0.006
Abbreviations: ACE, angiotensin converting enzyme; ACS, acute coronary syndrome; ARB, angiotensin receptor blocker; BMI, body mass index; CV, cardiovascular;
NSTEMI, Non ST-elevation myocardial infarction; PCI, percutaneous coronary intervention; SD, standard deviation; STEMI, ST-elevation myocardial infarction.
Missing values: 24 for BMI, 74 for education, 1 for diabetes, 1 for hypertension, 2 for smoking, 3 for previous MI 5 for ACS diagnosis, 8 for aspirin, 10 for statin, 13 for
beta-blockers, 15 for ACE inhibitor or ARB, 45 for Killip
https://doi.org/10.1371/journal.pone.0211464.t001
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secondary prevention programs after ACS. Knowing that premature ACS is associated with an
important negative impact on quality of life and high opportunity costs, intensive secondary
prevention interventions such as ELIPS can be considered of importance in patients with pre-
mature ACS, and may be especially interesting for the achievement of favourable long-term
outcomes.[19]
Table 2. Recommended therapies at discharge and at one year in standard care vs. ELIPS add-on groups.
Process Outcomes Standard Care
2009–2010
N = 1210
ELIPS
add-on
2011–2012
N = 1288
Age-sex adjusted
Rate Ratios
(95% CI)
P-value
Aspirin
Prescription at discharge, n (%) 1201 (99.4) 1268 (99.1) 1.00 (0.99–1.00) 0.32
Reported use at one year, n (%) 1098 (96.9) 1163 (97.2) 1.00 (0.99–1.01) 0.95
Statins
Prescription at discharge, n (%) 1182 (97.8) 1259 (98.5) 1.01 (0.99–1.02) 0.35
Reported use at one year, n (%) 1060 (93.6) 1101(92.1) 0.98 (0.96–1.00) 0.12
Beta-blockers
Prescription at discharge, n (%) 1015 (83.9) 1083 (84.1) 1.00 (0.97–1.04) 0.82
Reported use at one year, n (%) 861 (76.0) 959 (80.2) 1.05 (1.01–1.10) 0.019
ACE inhibitors or ARBs
Prescription at discharge, n (%) 1104 (91.3) 1159 (90.7) 0.99 (0.97–1.02) 0.57
Reported use at one year, n (%) 917 (80.9) 980 (82.0) 1.02 (0.98–1.06) 0.37
P2Y12 inhibitors
Prescription at discharge, n (%) 1140 (99.9) 1224 (99.0) 0.99 (0.98–1.00) 0.001
Reported use at one year, n (%) � 889 (97.5) 905 (81.0) 0.83 (0.80–0.86) < 0.001
Attendance to CR after discharge, n (%) 730 (65.6) 860 (72.9) 1.08 (1.02–1.14) 0.006
Abbreviations: ACE, angiotensin converting enzyme; ARB, angiotensin receptor blocker; CI, confidence intervals; CR, cardiac rehabilitation. Missing values at
discharge: 11 for aspirin, 12 for statins, 13 for beta-blockers, 12 for ACE inhibitors/ARBs and 120 for P2Y12 inhibitors. Missing values at one year (appropriate or not):
169 for aspirin, 170 for statins, 169 for beta-blockers, 170 for ACE inhibitors/ARBs, 469 for P2Y12 inhibitors and 206 for attendance to CR
� When adding missing values and reasons of therapy discontinuation, the reported use of P2Y12 inhibitors was nearly similar in both groups (85.8% vs. 84.4%). The
reported use of P2Y12 inhibitors did, however, change over time; clopidogrel from 70.5% to 37.6%, prasugrel from 28.7% to 47.9% and ticagrelor from 0% to 9.2%.
https://doi.org/10.1371/journal.pone.0211464.t002
Table 3. One-year major adverse cardiovascular events and secondary prevention targets in standard care vs. ELIPS add-on groups.
Standard
Care
2009–2010
N = 1210
ELIPS
Add-on
2011–2012
N = 1288
Age-sex
Adjusted
Hazard Ratios
(95% CI)
P-value
Total MACE�, n (%) 151 (12.5) 153 (11.9) 0.97 (0.77–1.22) 0.79
Cardiac death, MI and stroke, n (%) 75 (6.2) 73 (5.7) 0.92 (0.66–1.30) 0.65
All-cause death, n (%) 34 (2.8) 29 (2.3) 1.02 (0.62–1.68) 0.95
Cardiac death, n (%) 21 (1.7) 17 (1.3) 0.96 (0.50–1.84) 0.91
MI, n (%) 39 (3.2) 50 (3.9) 1.14 (0.73–1.78) 0.56
Stroke, n (%) 20 (1.7) 13 (1.0) 0.64 (0.30–1.36) 0.25
Revascularization, n (%) 82 (6.8) 90 (7.0) 0.99 (0.73–1.35) 0.95
Hospitalization for unstable angina 24 (2.0) 29 (2.3) 1.15 (0.67–1.98) 0.61
Lower limb ischemia, n (%) 14 (1.2) 12 (0.9) 0.85 (0.39–1.84) 0.68
Abbreviations: CI, confidence intervals; MACE, major adverse cardiovascular events; MI, myocardial infarction
https://doi.org/10.1371/journal.pone.0211464.t003
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Significance of the ELIPS intervention
Our study is, to our knowledge, the most comprehensive multi-level healthcare quality
improvement program performed so far in Europe. When measuring the outcomes of health
promotion interventions such as ELIPS, several aspects should be considered: (1) the propor-
tion of patients who actually received the intervention compared to the total pool of eligible
patients, (2) the efficacy of the intervention program on clinical and behavioural outcomes, (3)
a quantified assessment of adoption uptake of the program by centers, (4) the feasibility of
extending the intervention outside the hospital setting, and (5) the sustainability of the pro-
gram.[20] The ELIPS intervention is characterized by optimal reach, implementation and
adoption, but perhaps suboptimal efficacy on clinical outcomes. The long-term integration of
educational and quality of care programs into standard care needs to be supported by health-
care decision makers. In Switzerland, the hospital payment system is based on DRGs, which
include incentives to shorten the length of hospital stays.[10] Although shortening hospital
stays could be considered a barrier for the implementation of hospital-based multidimensional
CR programs, standardization of preventive efforts coupled with a well-structured educational
program can optimize the process of care for post-ACS patients. The high attendance rate to
CR programs observed in our study underlines the importance of implementing secondary
Fig 2. Cumulative hazards for the composite endpoints of cardiac death, myocardial infarction and stroke events over a follow-up period of 365
days in the standard care vs. the ELIPS add-on groups (logrank, P = 0.26). Abbreviations; MI, myocardial infarction.
https://doi.org/10.1371/journal.pone.0211464.g002
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prevention early after ACS at the hospital level.[21] In this regard, the ELIPS intervention
proved to be effective in encouraging patients to enrol in CR programs. Patients are sensitive
to the delivery of preventive messages during their hospital stay and these moments which are
focused on education are essential elements of patient-centered care and patient education.
[14] Despite these findings, the uptake of CR programs appears to be underused, most likely
Fig 3. One-year incidence of the composite endpoints of cardiac death, myocardial infarction and stroke events in the standard care vs. the ELIPS
add-on groups according to baseline characteristics. Abbreviations: ACS, acute coronary syndromes; CI, confidence intervals; STE-ACS, ST-elevation
acute coronary syndromes; NSTE-ACS, non ST-elevation acute coronary syndromes.
https://doi.org/10.1371/journal.pone.0211464.g003
Table 4. One-year major adverse cardiovascular events in standard care vs. ELIPS add-on groups in the premature ACS group (N = 779,� 55 years old).
Standard
Care
2009–2010
N = 342
ELIPS
Add-on
2011–2012
N = 437
Age-sex
Adjusted
Hazard Ratios
(95% CI)
P-value
Total MACE�, n (%) 33 (9.7) 39 (8.9) 0.85 (0.53–1.38) 0.97
Cardiac death, MI and stroke, n (%) 15 (4.4) 13 (3.0) 0.60 (0.27–1.33) 0.21
Abbreviations: CI, confidence intervals; MACE, major adverse cardiovascular events; MI, myocardial infarction
� Composite endpoints of MACE comprised all-cause death, myocardial infarction, stroke, coronary revascularization, hospitalization for unstable angina, lower limb
ischemia.
https://doi.org/10.1371/journal.pone.0211464.t004
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because of the lack of well-established processes of care.[5] As to the effect that such programs
can have on smoking cessation, we observed an approximate 48% cessation rate in the overall
cohort, with a remaining 40% of ongoing smokers, which suggests that more specific motiva-
tional and medicinal techniques may be required.
Comparison with previous studies
We have previously shown that the quality of care was especially high in post-ACS patients,
with prescription rates reaching up to 100% for aspirin, statins or ACE inhibitors after exclud-
ing patients for whom prescription for these medicines was contra-indicated.[17], [22] The
ELIPS add-on intervention was successful in that it left little room for further improvement in
the rate of discharge prescriptions and impact on clinical outcomes. For instance, in ACS
Table 5. One-year major adverse cardiovascular events in standard care vs. ELIPS add-on groups in the elderly group (N = 444,� 75 years old).
Standard
Care
2009–2010
N = 267
ELIPS
Add-on
2011–2012
N = 177
Age-sex
Adjusted
Hazard Ratios
(95% CI)
P-value
Total MACE�, n (%) 51 (19.1) 32 (18.1) 1.00 (0.63–1.55) 0.97
Cardiac death, MI and stroke, n (%) 27 (10.1) 23 (13.0) 1.35 (0.76–2.38) 0.30
Abbreviations: CI, confidence intervals; MACE, major adverse cardiovascular events; MI, myocardial infarction
� Composite endpoints of MACE comprised all-cause death, myocardial infarction, stroke, coronary revascularization, hospitalization for unstable angina, lower limb
ischemia.
https://doi.org/10.1371/journal.pone.0211464.t005
Table 6. One-year secondary prevention targets in standard care vs. ELIPS add-on groups.
Recommended Targets Standard Care
2009–2010
N = 1210
ELIPS
Add-on
2011–2012
N = 1288
Age-sex
Adjusted
Rate Ratios
(95% CI)
P-value
Biologic parameters
LDL cholesterol < 1.8 mmol/l, n (%) 306 (31.9) 361 (35.5) 1.14 (1.01–1.29) 0.037
LDL cholesterol < 2.6 mmol/l, n (%) 670 (69.8) 756 (74.4) 1.07 (1.02–1.13) 0.012
Glucose < 7.0 mmol/l in non-diabetics, n (%) 752 (94.1) 786 (94.4) 1.00 (0.98–1.02) 0.96
Glycated haemoglobin < 7% in diabetics, n (%) 48 (53.3) 73 (56.6) 1.06 (0.82–1.35) 0.67
Systolic blood pressure < 140 mm Hg, n (%) 666 (66.5) 754 (73.4) 1.06 (1.01–1.13) 0.029
Weight reduction�5% in overweight or obese, n(%) 130 (19.2) 141 (19.4) 1.03 (0.83–1.28) 0.781
Questionnaire parameters
Smoking cessation, n (%) 195 (47.0) 229 (46.8) 0.99 (0.86.1.14) 0.87
Physically active (IPAQ), n (%) � 460 (48.3) 566 (54.2) 1.10 (1.01–1.20) 0.024
Health utility based on EQ-5D, mean (±SD) † 0.81 (0.16) 0.81 (0.17) NA 0.52
High self-reported adherence (MAS), n (%) ‡ 528 (56.3) 582 (54.8) 0.99 (0.92–1.07) 0.80
Abbreviations: EQ-5D, EuroQol-5 dimensions; IPAQ, international physical activity questionnaire; LDL, low-density lipoprotein; MAS, medication adherence scale;
NA, not applicable; SD, standard deviation.
� Physically active was defined at least by three days of intense-activity or five days of moderate activity per week.
† Health utility was derived from the EQ-5D questionnaire using European tariffs.
‡ High self-reported adherence was defined by a score of 0 on the Morisky Medical Adherence Scale.
Missing values (appropriate or not): 522 for LDL cholesterol, 422 for glucose in non-diabetics, 204 for glycated haemoglobin in diabetics; 469 for systolic blood pressure,
264 for weight reduction, 109 for smoking cessation, 500 for physical activity and 497 for self-reported adherence.
https://doi.org/10.1371/journal.pone.0211464.t006
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patients in Brazil, a multifaceted quality improvement intervention including educational
materials, reminders, algorithms, and case manager training were associated with a significant
increase of adherence to evidence-based therapies.[23] In a meta-analysis that examined a
wide variety of secondary programs including education or counselling with an exercise com-
ponent, a reduction of subsequent MI and mortality was observed,[24] possibly associated
with improved clinical outcomes. Another meta-analysis from our group suggested that in-
hospital multidimensional secondary prevention interventions after ACS were more effective
when including intervention at the provider or system levels, compared with patient-level
only interventions.[11] We also previously reported that the most common reason that was
provided by patients to justify therapy discontinuation in the out-patient setting was the
recommendation received by their own treating physician.[25]. As for the improvement of
LDL cholesterol targets observed in the ELIPS add-on phase, this might be explained by the
higher rate of participation to CR or the use of high-intensity statin therapy.[26] Regarding the
impact of ELIPS on clinical outcomes, the event rate in the observation phase was lower than
expected, [18] possibly because of the secular trend towards an overall improvement in the
prognosis of post-ACS patients.
Future outlook
Adherence to national and international guidelines on patient management has been associ-
ated with improved post-ACS patient outcomes.[1] Continuous monitoring of performance
indicators is strongly recommended by the ESC guidelines in order to minimize the unwar-
ranted variations of quality of care.[4] Several European countries have developed initiatives to
improve quality of care according to recommendations and propositions from the ESC (e.g.
the Myocardial Infarction National Audit Project [MINAP] registry in the UK). These perfor-
mance measures were also collected within the EUROASPIRE surveys that reported data on
the cardiovascular risk profile in coronary patients.[6] Other initiatives, such as the EUROAC-
TION Study Group, showed that the implementation of local cardiology programs accessible
for all hospitals and general practices was feasible.[27] During hospitalization, ACS patients
are more likely to be responsive to educational messages and thereby be motivated to follow
healthcare recommendations.[16] Therefore, the sustainability of education programs such as
the ELIPS add-on intervention is dependent on the support of leaders active in cardiovascular
prevention, as well as policy makers responsible for the reimbursement of preventive efforts by
hospital-payment systems.
Limitations
The before-after design is largely used in clinical research aimed at assessing the feasibility/
effectiveness of implementing complex interventions into the healthcare system, but it cannot
exclude potential confounding factors that might occur during the study.[2, 11] For instance,
since 2010 several Cantons in Switzerland have banned smoking in public areas, while at the
same time more potent antiplatelet therapies (P2Y12 inhibitors) have emerged as treatments of
choice. Furthermore, the study sample might not represent all patients hospitalized with ACS
(selection bias), as our patients were only included at university hospitals. In fact, not all
patients who had cardiogenic shock or undergone resuscitation were included, which perhaps
partly explains the low mortality rate in the entire cohort. In addition, study participants were
mainly recruited in the catheterization laboratory and might not be representative of those
patients not transferred to PCI centers. Although we quantified the utilization of the educa-
tional tools used in the ELIPS add-on intervention group, we did not measure the quality of
the motivational interviewing, nor did we evaluate whether the educational tools were
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appropriately used. In fact, we cannot exclude that the two days’ training program on motiva-
tional interviewing may not have been sufficient for some care-givers, in particular physicians.
Finally, given the non-long term duration of P2Y12 inhibitors, the data collection of the vari-
able could be a source of bias according to the date of the follow-up visit, as well as to the cardi-
ologist taking the decision to stop P2Y12 treatment.
Conclusion
The ELIPS program was designed after investigating areas of the healthcare system that offered
the greatest potential for improving the quality of care for ACS patients. Although the expected
impact on clinical outcomes in the overall cohort was not observed, the implementation of the
ELIPS program was associated with a significant improvement in participation in CR pro-
grams and control of cardiovascular risk factors. These results should encourage the pursuit of
long-term, hospital-based, post-ACS secondary prevention programs.
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